clinicaltrialvanguard

When the Scan Knows Before the Spirometer Does

Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT ...
clinicaltrialvanguard

Sionna to Test SION-451 and SION-2222 Combo in CF Phase 2a Trial

Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients ...
clinicaltrialvanguard

FDA Hears 80 Speakers on Psychedelic Drug Therapy Standards

FDA held public hearing on psychedelic drug therapy with 80 speakers. Explore debates on safety, credentialing, and equitable ...
Opinion
clinicaltrialvanguardOpinion

Compass Pathways Just Answered the Durability Question. Now Comes the Harder Problem.

Compass Pathways' 52-week COMP360 data shows 40-45% response rates in treatment-resistant depression. FDA approval in 2027 means nothing without ...
clinicaltrialvanguard

Ivonescimab beats pembrolizumab on survival in first-line PD-L1-positive NSCLC

Ivonescimab beats pembrolizumab on survival in first-line PD-L1-positive NSCLC, extending median OS by over eight months in Phase III trial.
clinicaltrialvanguard

Definium’s DT120 ODT Meets Primary Endpoint in Phase 3 GAD Study

Definium's DT120 ODT met its primary endpoint in Phase 3 testing for generalized anxiety disorder, potentially offering an alternative to decades-old SSRI and S ...